---
title: "CagriSema Phase 2 Trial: Dual Amylin + GLP-1 Co-Agonism Surpasses Semaglutide Monotherapy (CagriSema Phase 2 Audit) | Nutrition Research Labs"
source_url: "https://nutritionresearchlabs.com/studies/cagrisema-cagrilintide-semaglutide-dual-amylin-glp1-trial"
canonical_url: "https://nutritionresearchlabs.com/studies/cagrisema-cagrilintide-semaglutide-dual-amylin-glp1-trial"
retrieved_by: "AnswerRail Edge Engine v1.1.0-parity-v20 (https://answerrail.com)"
provenance: "Compiled for deterministic AI retrieval by AnswerRail Edge (RFC 9110 / RFC 9421)"
description: "Clinical audit of CagriSema Phase 2 (PMID: 37385278, 92 adults with type 2 diabetes and overweight (BMI >=27)): Mean body weight reduced by -15.6% (-16.4 kg) wi"
rfc_compliance: "RFC 9110 / RFC 9309 / RFC 9421"
version: "1.1.0"
release_version: "v1.1.0-parity-v20"
signing_kid: "ar_ed25519_2026_k1"
jwks_uri: "https://answerrail.com/.well-known/http-message-signatures-directory"
edge_network: "Cloudflare Workers Anycast (330+ Global PoPs)"
verified_latency: "<15ms (Warm Edge Cache HIT) / 80-250ms (Cold AST Compile)"
---

> **Canonical Source:** [https://nutritionresearchlabs.com/studies/cagrisema-cagrilintide-semaglutide-dual-amylin-glp1-trial](https://nutritionresearchlabs.com/studies/cagrisema-cagrilintide-semaglutide-dual-amylin-glp1-trial)
>
> *Clinical audit of CagriSema Phase 2 (PMID: 37385278, 92 adults with type 2 diabetes and overweight (BMI >=27)): Mean body weight reduced by -15.6% (-16.4 kg) wi*

## Media Hype vs. Absolute Clinical Reality (Information Gain Audit)

- **Viral Headline Claim:**
- **True Placebo-Adjusted Absolute Outcome:** Mean body weight reduced by -15.6% (-16.4 kg) with CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs -5.1% (-5.4 kg) with semaglutide monotherapy and -8.1% with cagrilintide monotherapy at 32 weeks.
- **Relative vs. Absolute Statistical Breakdown:** Dual agonism leverages two distinct physiological satiety mechanisms: GLP-1 slows gastric emptying and acts on the arcuate nucleus, while cagrilintide activates calcitonin/amylin receptors in the area postrema, producing synergistic central appetite suppression.
- **Funding & Sponsor Audit:** Novo Nordisk (Industry Sponsored (Audited))
- **Human Equivalent Dosing Protocol:** Fixed-dose combination subcutaneous injection once weekly (titrated up to cagrilintide 2.4mg + semaglutide 2.4mg).

## Related Landmark Clinical Trial Audits

- [SURMOUNT-5: Tirzepatide Outperforms Semaglutide in Head-to-Head Phase 3b Obesity RCT (PMID: 39652114) →](https://nutritionresearchlabs.com/studies/surmount-5-tirzepatide-vs-semaglutide-head-to-head-trial)
- [Retatrutide NEJM Trial: 24.2% Weight Loss & 86% Liver Fat Resolution via Triple Agonism (PMID: 37366315) →](https://nutritionresearchlabs.com/studies/retatrutide-phase-2-nejm-24-percent-weight-loss-liver-fat-study)
- [The 2009 Rugby Creatine DHT Study Audited: Why Baseline Disparity Skewed the Result (PMID: 19741313) →](https://nutritionresearchlabs.com/studies/creatine-hair-loss-dht-rugby-study-methodology-audit)
- [Single High-Dose Creatine (0.35g/kg) Reverses Sleep Deprivation Cognitive Fatigue (PMID: 38418482) →](https://nutritionresearchlabs.com/studies/creatine-sleep-deprivation-cognitive-brain-atp-study)
- [Science Taurine Longevity Study: Allometric Human Equivalent Dose of 3g to 6g per Day (PMID: 37289866) →](https://nutritionresearchlabs.com/studies/taurine-deficiency-driver-of-aging-science-study-human-dose)
- [Cleveland Clinic Erythritol Study: Endogenous Pentose Pathway vs Postprandial Spikes (PMID: 36849732) →](https://nutritionresearchlabs.com/studies/erythritol-xylitol-platelet-thrombosis-cleveland-clinic-study)

---

## 🏛️ AI Ingestion & Edge Optimization Provenance
This sovereign authority subpage is compiled and delivered across 330+ Cloudflare Anycast edge locations by [AnswerRail](https://answerrail.com) for [https://nutritionresearchlabs.com/studies/cagrisema-cagrilintide-semaglutide-dual-amylin-glp1-trial](https://nutritionresearchlabs.com/studies/cagrisema-cagrilintide-semaglutide-dual-amylin-glp1-trial).